Arcus Biosciences, Inc.
RCUS
$22.43
$0.220.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 21.48% | -- | 100.00% | -19.15% | -2.17% |
| Total Depreciation and Amortization | 50.00% | 0.00% | -33.33% | 0.00% | 50.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -13.33% | 15.38% | -7.14% | 0.00% | -6.67% |
| Change in Net Operating Assets | -242.86% | 114.19% | -300.00% | -60.87% | -122.77% |
| Cash from Operations | -23.71% | 27.07% | -0.76% | -32.00% | -484.62% |
| Capital Expenditure | -- | -- | 100.00% | 0.00% | 0.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -329.11% | -42.34% | 315.15% | -36.54% | 285.71% |
| Cash from Investing | -330.38% | -42.34% | 328.13% | -37.25% | 275.86% |
| Total Debt Issued | -- | -100.00% | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,475.00% | 166.67% | -97.89% | 4,633.33% | 50.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -400.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,475.00% | -84.62% | -63.38% | 7,200.00% | -104.17% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -60.00% | -117.86% | 33.33% | 182.35% | -213.33% |